Calliditas Therapeutics AB Return on Equity

Calliditas Therapeutics AB (CALT) currently reports a ROE of -1172.24%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Calliditas Therapeutics AB's ROE history and peer comparisons.

Calliditas Therapeutics AB's ROE of -1172.24% is lower than the Healthcare sector average of 11.15%. That is roughly 10609.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Calliditas Therapeutics AB's current -1172.24% should be judged against Healthcare norms (sector average: 11.15%) and against CALT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -1172.24%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Calliditas Therapeutics AB, and consider following CALT for alerts when major investors trade the stock.

Calliditas Therapeutics AB is classified in the Healthcare sector. On ROE, it currently shows -1172.24% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CALT with unrelated industries.